Tempest Therapeutics shares rose 35.74% to $1.03 Wednesday after the company announced an exclusive option agreement with Hebei Senlang Biotechnology. The deal covers Senlang’s CD7-targeted lentiviral vector platform, which is designed to generate CAR-T and CAR-NK cells inside the body, and a portfolio of in vivo CAR-T candidates. The portfolio includes a BCMA/GPRC5D dual-targeting candidate in Phase 1 dose-escalation trials for relapsed or refractory multiple myeloma, as well as preclinical programs for blood cancers and autoimmune diseases. Tempest said the platform would complement its CD7-targeted lipid nanoparticle program, including lead candidate TPST-4003, by offering a potentially durable approach alongside transient CAR expression. The company also announced a $2.5 million warrant-based private placement. Earlier trading reports showed a 49.6% premarket gain to $1.13 and an after-hours increase of 66.53% to $1.26, while shares had closed Tuesday’s regular session down 3.68% at $0.76.